Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO ...

Novartis AG stock hit a 52-week high then corrected. Click for NVS Q1 earnings expectations, Entresto sales outlook, and why ...

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...

) has been revised to $149.84 / share. This is an increase of 10.96% from the prior estimate of $135.04 dated November 16, 2025. The price target is an average of many targets provided by analysts.

Novartis AG (NYSE:NVS) is one of the top cheap pharmaceutical stocks to buy now. In a report released on August 1, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NYSE:NVS) ...

Novartis AG (NYSE: NVS) released data on Thursday from the KALUMA Phase 3 study for the new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). GanLum is ...

Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and ...

In addition to UBS, Novartis AG also received a Hold from Barclays’s James Gordon CFA in a report issued on March 27. However, on April 2, Kepler Capital maintained a Buy rating on Novartis AG (Six ...

Inclusive Health Accelerators (IHAs): a new community-based initiative launching across five U.S. cities this week, which aims to close gaps in access to breast and prostate cancer care communities ...